Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis.
- Author:
Seung Sook PAIK
1
;
In Kyoung HWANG
;
Myung Jae PARK
;
Seung Hyeun LEE
Author Information
- Publication Type:Original Article
- Keywords: Lung; Carcinoma; Pemetrexed; Chemotherapy; Platinum; Receptor, Epidermal Growth Factor
- MeSH: Adenocarcinoma*; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Therapy*; Humans; Lung Neoplasms; Lung*; Maintenance Chemotherapy; Multivariate Analysis; Pemetrexed*; Platinum; Receptor, Epidermal Growth Factor; Retrospective Studies*; Standard of Care; Survival Rate
- From:Tuberculosis and Respiratory Diseases 2018;81(2):148-155
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Although targeted therapy and immuno-oncology have shifted the treatment paradigm for lung cancer, platinum-based combination is still the standard of care for advanced non-small cell lung cancer (NSCLC). Pemetrexed continuation maintenance therapy has been approved and increasingly used for patients with nonsquamous NSCLC. However, the efficacy of this strategy has not been proven in patients without driving mutations. The objective of this study was to compare the clinical benefit of pemetrexed continuation maintenance to conventional platinum-based doublet in epidermal growth factor receptor (EGFR)-negative lung adenocarcinoma. METHODS: A total of 114 patients with EGFR-negative lung adenocarcinoma who were treated with platinum doublet were retrospectively enrolled. We compared the survival rates between patients received pemetrexed maintenance after four-cycled pemetrexed/cisplatin and those received at least four-cycled platinum doublet without maintenance chemotherapy as a first-line treatment. RESULTS: Forty-one patients received pemetrexed maintenance and 73 received conventional platinum doublet. Median progression-free survival (PFS), which was defined as the time from the day of response evaluation after four cycles of chemotherapy to disease progression or death, was significantly higher in the pemetrexed maintenance group compared to conventional group (5.8 months vs. 2.2 months, p<0.001). Median overall survival showed an increasing trend in the pemetrexed maintenance group (22.3 months vs. 16.1 months, p=0.098). Multivariate analyses showed that pemetrexed maintenance chemotherapy was associated with better PFS (hazard ratio, 0.73; 95% confidence interval, 0.15–0.87). CONCLUSION: Compared to conventional platinum-based chemotherapy, premetrexed continuation maintenance treatment is associated with better clinical outcome for the patients with EGFR wild-type lung adenocarcinoma.
